Prolactin: What Your Number Changes About Your Treatment

What Prolactin Actually Does

Prolactin is a 199-amino-acid polypeptide hormone secreted by lactotroph cells in the anterior pituitary gland. Its primary known role is lactation, but its receptor appears in over 300 biological processes, ranging from immune regulation to reproductive signaling [1]. The hypothalamus keeps prolactin in check through tonic dopamine inhibition via tuberoinfundibular neurons. When that brake fails, prolactin rises.

For men and women on hormone therapy, prolactin is not a passive bystander. It feeds back on the hypothalamic-pituitary-gonadal (HPG) axis by suppressing gonadotropin-releasing hormone (GnRH) pulsatility [2]. That suppression reduces luteinizing hormone (LH) and follicle-stimulating hormone (FSH) output. The downstream effect: lower testosterone in men, disrupted ovulation in women. A 2019 Endocrine Society clinical practice guideline explicitly recommends measuring prolactin in any patient presenting with hypogonadal symptoms before initiating testosterone therapy [3].

The test itself is straightforward. A single fasting morning blood draw is standard. Prolactin follows a pulsatile and diurnal secretion pattern, peaking during sleep and declining through the morning hours [1]. Stress, nipple stimulation, and recent meals can all produce transient spikes. A mildly elevated result (under 40 ng/mL) warrants a confirmatory repeat before clinical action.

Normal Ranges and What the Numbers Mean

Reference ranges vary slightly between laboratories, but the Endocrine Society and most major reference labs align on these thresholds: non-pregnant women fall between 2 and 29 ng/mL, men between 2 and 18 ng/mL, and pregnant women may reach 200 ng/mL or higher by the third trimester [4].

These numbers are not arbitrary cutoffs. They reflect population-based distributions where values above the upper limit carry a statistically meaningful risk of reproductive dysfunction. A 2011 meta-analysis published in the Journal of Clinical Endocrinology & Metabolism found that men with prolactin levels above 25 ng/mL had a 3.4-fold increased likelihood of presenting with erectile dysfunction and decreased libido compared to age-matched controls [5].

The clinical significance of a prolactin result depends heavily on the magnitude of elevation:

Mild elevation (25 to 100 ng/mL): Most often drug-induced. Antipsychotics, particularly risperidone (which can raise prolactin above 100 ng/mL in some patients), SSRIs, metoclopramide, and domperidone are common culprits [6]. Stress-related or idiopathic hyperprolactinemia also falls in this range.

Moderate elevation (100 to 250 ng/mL): This range makes the Endocrine Society's 2011 guideline recommend pituitary MRI to evaluate for a microprolactinoma (tumor <10 mm) [4].

Severe elevation (above 250 ng/mL): Nearly diagnostic of a macroprolactinoma. The higher the number, the larger the tumor tends to be. Levels above 1 to 000 ng/mL correlate with invasive macroadenomas extending beyond the sella turcica [4].

One technical caveat: the "hook effect." Extremely high prolactin concentrations (often above 10 to 000 ng/mL) can paradoxically read as normal or mildly elevated on standard immunoassays because excess antigen saturates both capture and detection antibodies [7]. If a patient has a large pituitary mass but a "normal" prolactin, the clinician should request serial dilution of the sample.

How High Prolactin Changes Testosterone Therapy

Elevated prolactin is one of the most clinically significant findings that can redirect a TRT protocol. Here is why. Hyperprolactinemia suppresses GnRH pulsatility at the hypothalamic level [2]. This means the pituitary receives a weaker signal to produce LH and FSH. Even if a man is already on exogenous testosterone, the underlying cause of high prolactin (whether a prolactinoma or a medication side effect) still matters for long-term management.

The Endocrine Society's 2018 guideline on male hypogonadism states: "Serum prolactin should be measured in men with low testosterone levels, particularly when the total testosterone is below 150 ng/dL or when there are symptoms of mass effect such as headache or visual field deficits" [3]. Dr. Shalender Bhasin, the guideline's lead author, noted that "identifying and treating the cause of hyperprolactinemia may restore endogenous testosterone production, making TRT unnecessary in select patients" [3].

For men already receiving TRT who are found to have prolactin above 50 ng/mL, the clinical algorithm typically proceeds as follows:

1. Rule out medication causes. If the patient takes an antipsychotic or antiemetic known to raise prolactin, a supervised medication switch (with the prescribing psychiatrist or gastroenterologist) is the first intervention [6].
2. Order pituitary MRI. Any prolactin above 100 ng/mL, or any level accompanied by visual symptoms or persistent headache, warrants imaging per Endocrine Society guidelines [4].
3. Consider cabergoline. For confirmed prolactinomas, cabergoline 0.25 to 0.5 mg twice weekly normalizes prolactin in approximately 85% of patients within 3 to 6 months [8]. Bromocriptine is an alternative but carries a higher side-effect burden.
4. Reassess TRT need. After prolactin normalization, repeat total testosterone and free testosterone at 6 to 8 weeks. A subset of men (estimates range from 30% to 50% in case series) recover enough endogenous production to discontinue TRT entirely [3].

This sequence explains why a single lab value can reshape an entire treatment plan. Starting or continuing TRT without checking prolactin risks masking a treatable pituitary adenoma while the tumor grows.

How High Prolactin Changes Women's Hormone Therapy

In women, hyperprolactinemia is the most common pituitary cause of secondary amenorrhea and anovulatory infertility [4]. The mechanism mirrors what happens in men: elevated prolactin suppresses GnRH, which in turn reduces FSH and LH, stalling follicular development.

For women on estrogen-based HRT for menopausal symptoms, a newly discovered prolactin elevation above 50 ng/mL prompts a different set of questions. Is this a prolactinoma that was undetected during reproductive years? Is the estrogen formulation contributing? Oral estrogens undergo first-pass hepatic metabolism and can modestly increase prolactin (typically <5 ng/mL), while transdermal formulations show minimal effect on prolactin levels [9].

A 2020 study published in Fertility and Sterility (N=342) found that women with prolactin levels between 30 and 100 ng/mL who were treated with cabergoline had ovulation restoration rates of 72% within 6 months [10]. The Endocrine Society recommends that women with hyperprolactinemia who desire pregnancy receive a dopamine agonist rather than surgery as first-line treatment, given the high response rate and low surgical cure rates for microadenomas (roughly 70 to 80% initial remission but 20 to 50% recurrence within 5 years) [4].

For women not seeking pregnancy, the decision is more nuanced. If prolactin is mildly elevated but the patient has regular menses and adequate estrogen levels, observation with serial prolactin monitoring every 6 to 12 months may be appropriate. Bone density becomes the key concern: prolonged hypoestrogenism driven by high prolactin accelerates trabecular bone loss. A study in the Journal of Bone and Mineral Research documented a 5 to 8% reduction in lumbar spine BMD over 2 years in untreated hyperprolactinemic women compared to age-matched controls [11].

Drug-Induced Hyperprolactinemia: The Medication Factor

Medications are the single most common cause of non-physiologic prolactin elevation, accounting for roughly 25 to 40% of all cases of hyperprolactinemia seen in endocrine practice [6]. This is not a minor footnote. It changes prescribing decisions across psychiatry, gastroenterology, and hormone therapy simultaneously.

The mechanism is consistent across drug classes: blockade of dopamine D2 receptors on lactotroph cells removes the tonic inhibition that normally keeps prolactin secretion in check. The degree of elevation depends on the potency and selectivity of D2 antagonism.

Highest-risk medications:

• Risperidone and paliperidone: prolactin elevations above 100 ng/mL are common, sometimes exceeding 200 ng/mL [12]. A 2004 study in Psychoneuroendocrinology found risperidone raised prolactin to a mean of 81 ng/mL in male patients (N=95) after 6 weeks [12].
• Haloperidol and first-generation antipsychotics: mean elevations of 40 to 60 ng/mL.
• Metoclopramide: can exceed 200 ng/mL with chronic use.

Moderate-risk medications:

• SSRIs (sertraline, fluoxetine, paroxetine): typical elevations of 5 to 30 ng/mL [6].
• Tricyclic antidepressants: modest effect, usually <20 ng/mL above baseline.

Lower-risk or prolactin-sparing antipsychotics:

• Aripiprazole, cariprazine, and brexpiprazole act as partial D2 agonists. Aripiprazole can actually decrease elevated prolactin. A 2008 study in the American Journal of Psychiatry showed that adding aripiprazole to risperidone-treated patients (N=56) reduced prolactin by a mean of 74% within 8 weeks [13].

This creates a direct clinical tension for patients who need both psychiatric medication and hormone therapy. The practical resolution, as the AACE 2020 position statement recommends, is to collaborate across specialties: an endocrinologist, a psychiatrist, and (when relevant) a reproductive endocrinologist should jointly decide whether to switch medications, add a dopamine agonist, or accept a mildly elevated prolactin and monitor downstream effects [4].

How to Lower Prolactin

Lowering prolactin depends entirely on the cause. The approach for a prolactinoma differs from the approach for a drug-induced elevation, and both differ from idiopathic cases.

Prolactinoma (micro or macro): Cabergoline is first-line. The standard starting dose is 0.25 mg twice per week, titrated upward every 4 weeks based on prolactin response [4]. The 2011 Endocrine Society guideline states that "cabergoline is preferred over bromocriptine because of its higher efficacy rate, less frequent dosing, and better tolerability" [4]. Tumor shrinkage of 50% or more occurs in approximately 80% of macroprolactinomas treated with cabergoline [8]. Cardiac valvulopathy, a concern raised by studies of high-dose cabergoline in Parkinson disease, has not been demonstrated at the lower doses used for prolactinomas (typically <2 mg/week) in a 2012 meta-analysis of 8 studies covering 500+ patients [14].

Drug-induced elevation: Switching to a prolactin-sparing agent is the preferred strategy when psychiatrically safe. If switching is not possible, adding low-dose aripiprazole (2 to 5 mg/day) as an adjunct can normalize prolactin in many patients without disrupting the primary psychiatric medication's efficacy [13].

Lifestyle and physiologic factors: Sleep deprivation, chronic stress, and chest wall irritation (including certain bras and piercings) can cause mild prolactin elevations. Correcting these factors may lower prolactin by 5 to 15 ng/mL, though evidence is limited to small observational studies. Vitamin B6 (pyridoxine) has theoretical support as a dopamine cofactor, but no randomized controlled trial has demonstrated clinically significant prolactin reduction with supplementation [6].

Macroprolactin screening: Up to 25% of patients with apparent hyperprolactinemia actually have macroprolactinemia, a condition where prolactin circulates bound to IgG antibodies in a high-molecular-weight complex [7]. Macroprolactin is biologically inactive. If a patient has elevated total prolactin but no symptoms, a polyethylene glycol (PEG) precipitation test can determine the proportion of monomeric (bioactive) prolactin [7]. If macroprolactin accounts for the elevation, no treatment is needed.

Low Prolactin: What It Means

Low prolactin receives far less clinical attention, but it carries its own implications. A prolactin level below 2 ng/mL may signal anterior pituitary insufficiency, particularly when other pituitary hormones (TSH, ACTH, GH, LH, FSH) are also low [1].

Sheehan syndrome (postpartum pituitary necrosis) is the classic cause of persistently low prolactin in women. The inability to lactate postpartum is often the first clinical sign. Outside of this context, isolated low prolactin is uncommon and usually does not require specific treatment. There is emerging research suggesting that very low prolactin may be associated with metabolic syndrome and reduced immune function, but these findings come from cross-sectional studies and do not yet support clinical intervention [15].

For men on TRT, a low prolactin is generally not concerning. Exogenous testosterone suppresses LH, but prolactin is regulated primarily by dopamine, not gonadotropins. A low reading in the context of normal pituitary function on other axes requires no action.

When and How Often to Recheck Prolactin

Timing matters. Prolactin should be drawn fasting, in the morning, at least 1 hour after waking, and ideally without significant physical or emotional stress beforehand [4]. Avoid blood draws immediately after breast examination or exercise.

For patients on dopamine agonist therapy, the Endocrine Society recommends rechecking prolactin 4 weeks after each dose adjustment [4]. Once prolactin normalizes, monitoring shifts to every 6 months for the first year, then annually. MRI follow-up for macroprolactinomas should occur at 3 months after starting cabergoline, then annually if the tumor is shrinking.

For patients on medications known to raise prolactin, a baseline prolactin before starting the drug (or as soon as possible after) and a follow-up at 3 months is reasonable clinical practice [6]. If the level is elevated but symptoms are absent, annual monitoring with attention to menstrual regularity, libido, and bone density suffices.

Patients initiating TRT should have prolactin measured at baseline. If normal, repeat testing is not routinely needed unless symptoms of prolactin excess develop (galactorrhea, new-onset sexual dysfunction not explained by testosterone levels, visual changes) [3].

The minimum recheck interval for any clinical decision is 4 weeks, because prolactin has a half-life of approximately 20 to 30 minutes but pituitary secretory dynamics require weeks to reach a new steady state after an intervention [1].